original ) (raw )Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Liliane Fossati-Jimack
The Lancet
View PDFchevron_right
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register
Ralph Nisell
Rheumatology, 2018
View PDFchevron_right
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Briana Hudson
Nature Medicine
View PDFchevron_right
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
Liliane Fossati-Jimack
Efficacy and mechanism evaluation, 2022
View PDFchevron_right
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
C. Bingham , Neil Collinson
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Delphine Courvoisier , Axel Finckh
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Rituximab for rheumatoid arthrits treatment: a systematic review
Juliana de Oliveira Costa
Revista Brasileira de Reumatologia (English Edition), 2014
View PDFchevron_right
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
Meliha Kapetanovic
Rheumatology, 2007
View PDFchevron_right
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
Helena D'Elia
Annals of the rheumatic diseases, 2018
View PDFchevron_right
Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
I. Ancuta
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital
S. Mathieu
Arthritis Care & Research, 2013
View PDFchevron_right
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Mark Genovese
Arthritis & Rheumatism, 2006
View PDFchevron_right
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
Axel Finckh
Arthritis & Rheumatism, 2007
View PDFchevron_right
SAT0229 Effectiveness of Repeated Courses of Rituximab in RA – Results from the Cererra Collaboration
Katerina Chatzidionysiou
Annals of the Rheumatic Diseases, 2014
View PDFchevron_right
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
Francisco Blanco
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials
Joachim Listing
Arthritis & Rheumatism, 2006
View PDFchevron_right
anti-TNF agent? (TNF) agents after previous failure of an versus alternative anti-tumour necrosis factor arthritis benefits from switching to rituximab Which subgroup of patients with rheumatoid
Anca I Ciurea
2010
View PDFchevron_right
Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial
john sampalis
Medical Science Monitor, 2012
View PDFchevron_right
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis
R. Pellerito , Luca Quartuccio , P. Puttini
Rheumatology, 2009
View PDFchevron_right
Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers
Anamika Arora
International Journal of Rheumatology, 2013
View PDFchevron_right
Long-Term Drug Survival of TNF Inhibitor Therapy in RA
Anamika Arora
2013
View PDFchevron_right
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
R. Moots , L. Barile-fabris
Annals of the Rheumatic Diseases, 2014
View PDFchevron_right
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy
Yasser Elsherbiny
Annals of the Rheumatic Diseases, 2014
View PDFchevron_right
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
Paul Tak
Annals of the Rheumatic Diseases, 2008
View PDFchevron_right
Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial
john sampalis
Arthritis Care & Research, 2013
View PDFchevron_right
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
Christopher McCabe
Health technology assessment (Winchester, England), 2018
View PDFchevron_right